The Food and Drug Administration classified 13 separate recall records on August 31, covering Medline convenience kits distributed nationwide, and the products involved include the prep trays used for cesarean sections and vaginal deliveries. The FDA record for the cesarean prep tray lists 222,653 units in commerce for the recall event.
The defect is not in the tray. It is in one component inside it. Each affected kit contains a BD ChloraPrep Clear 1 mL applicator, the single-use swab used to disinfect skin immediately before a needle, incision, or catheter goes in. Some of those applicator pouches may carry what the FDA record describes as an open or incomplete seal.
For patients, the near-term consequence is not something to check at home. Nobody has one of these trays in a medicine cabinet. It is a question worth raising if you or a family member had surgery, gave birth, or had a catheter placed at a U.S. hospital in recent months and then developed an unexplained infection at the site.
The 13 Records the FDA Posted in Late August
All 13 records share a single recall event ID, 99561, and were classified as Class II, the FDA's middle severity tier. The full event listing shows the range of kit types affected, and the breadth is the story.
Alongside the cesarean prep tray, the event covers a labor kit and vaginal delivery admission bag, an open heart pack, blood culture kits, IV start kits, an orthopedic aspiration kit, eye basin trays, patient admission kits, and several general pre-operative kits. These are the standardized, pre-assembled trays that let a clinical team open one package instead of gathering fifteen separate items.
The 222,653 figure appears identically on the individual records reviewed for this report, which indicates it is the total for the event rather than a per-product count. Reading it as the number of cesarean trays alone would overstate that specific product substantially.
Medline initiated the action on July 20 and began notifying customers by first-class mail and email the same day. The FDA determined the cause was a nonconforming material or component.
Tracing the Defect Back to a Single Supplier
Medline did not manufacture the failing part. The recall is what the FDA record calls a downstream recall, triggered after BD recalled specific lots of its ChloraPrep Clear 1 mL applicators.
That upstream problem has produced more than one action this year. In June, BD issued a nationwide recall of specific applicator lots over microbial contamination. The FDA has also posted an update on a separate Medline convenience kit alert describing a different packaging defect involving wrinkles in the paper lidding of the same swab family.
MedicalDaily previously reported on how one recalled component can cascade through many assembled kits. These classifications are the largest single-day expression of that pattern so far this year, and they extend it into obstetric care.
Patients Who Had Surgery or Gave Birth in Recent Months
The lot codes listed on the labor and delivery record run from 2024 production through 2026, and the recall remains open, meaning not all product has been corrected.
Medline's stated risk is a localized skin or soft tissue infection, or a systemic infection or infectious complication. The FDA recall records reviewed for this report do not report any injuries.
Risk is not evenly distributed. A patient recovering from a cesarean has a fresh abdominal incision. A patient with a central line or an arterial line has a direct route into the bloodstream. People receiving chemotherapy, taking immunosuppressants, living with poorly controlled diabetes, or recovering from a transplant clear a bacterial exposure less readily than a healthy adult after a routine blood draw.
Signs of a surgical or procedure site infection include redness spreading outward from the site, warmth, swelling, new or worsening pain after the first few days, drainage that is cloudy or foul-smelling, and fever. New parents recovering from a cesarean should treat a fever above 100.4 degrees Fahrenheit, or a wound that starts hurting more instead of less, as a reason to call the delivering provider rather than wait for the postpartum visit.
Over-Labeling Instead of Return, and the Gap It Creates
The corrective action here is unusual and worth understanding. Medline is not asking facilities to send kits back. Customers request stickers to over-label affected kits with an instruction telling staff to remove the affected applicator and replace it from separate supply. No kits are to be returned.
That approach keeps needed trays in circulation during a supply crunch, which is a reasonable trade. It also means correction depends on individual clinicians reading a sticker in the moment. Compliance cannot be verified from outside the facility, and the FDA records do not publish facility-level completion rates.
Facilities should also note that the instruction has not stayed fixed across every Medline notification. In a related action covering different lots, the company told customers in August to destroy entire kits rather than swap the applicator, after receiving further information from BD about fungal contamination.
For readers, that translates into one legitimate question rather than alarm. Anyone with a planned procedure can ask whether their hospital received the Medline notice and completed the correction. The FDA's explanation of medical device recalls notes that a record stays open until all affected product is corrected or removed, and this one has not closed.
Nobody should postpone a medically necessary surgery or delivery over a Class II component recall. The FDA has not restricted use of these kits. Problems can be reported to the FDA through MedWatch, and updated status will appear on the individual recall records.
Key Questions Answered
What exactly was recalled? Thirteen records covering Medline convenience kits that contain BD ChloraPrep Clear 1 mL applicators. Affected applicator pouches may have an open or incomplete seal.
Do I have any of this at home? No. These are hospital and clinic procedure trays. They are not sold to consumers.
Does 222,653 mean that many cesarean trays? No. That figure represents the event total across every affected kit type, not one product.
Should I cancel a scheduled surgery or delivery? No. The FDA has not restricted use. Facilities were instructed to remove and replace the affected component.
Which patients face the most risk? People with fresh surgical incisions, central or arterial lines, and anyone immunocompromised, including cancer patients and transplant recipients.
What symptoms should I watch for after a procedure? Spreading redness, warmth, swelling, pain that worsens after the first few days, cloudy or foul-smelling drainage, or fever.
Has anyone been harmed? The FDA recall records reviewed for this report do not report any injuries. The action is a precaution based on a packaging defect, not on confirmed infections.
